Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(1):25-30
In May 2016 the U.S. Food and Drug Administration (FDA) approved changes to the labels of fluoroquinolone drugs for systemic use and advised to restrict their prescribing for the treatment of acute sinusitis, uncomplicated urinary tract infections …